Nick Shah
Role: Associate
Sites: CDL-Toronto, CDL-Vancouver
Streams: Biomedical Engineering, Cancer
Nick Shah is a passionate and accomplished scientific leader with extensive experience leading successful drug discovery programs. He is driven by a deep commitment to scientific innovation and a desire to make a positive impact on human health.
Nick has a proven track record of success in driving the advancement of drug candidates from early discovery stages through preclinical development. Recently, he led Quantitative Biology at Nura Bio: a team dedicated to identifying and developing innovative therapies for neurodegenerative disease. Nura Bio discovered NB-4746 which is currently in clinical testing.
Prior to joining Nura Bio, Nick has held leadership positions at DICE Therapeutics, RAPT Therapeutics and Flexus Biosciences and has contributed to the discovery of five additional drugs in oncology and immunology as well as multiple successful corporate exits.
Nick completed his PhD at the University of Toronto and a Postdoctoral Fellowship at Stanford University.